ArticleScientific reports2026
Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic membranous nephropathy (MN) shows variable renal outcomes, and reliable histologic markers for risk stratification are limited. The global sclerotic glomeruli ratio (GSGR) may reflect chronic kidney damage and help predict progression, but its prognostic value and optimal threshold remain unclear. We retrospectively analyzed 322 patients with biopsy-proven idiopathic MN from the Turkish Society of Nephrology-Glomerular Diseases Study Group registry, excluding those with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m² at diagnosis or insufficient data. GSGR was calculated as the percentage of globally sclerotic glomeruli among total glomeruli. Histopathological parameters, including exudative glomerular changes, tubular atrophy/interstitial fibrosis (TA/IF), and vascular alterations, were semi-quantitatively graded according to the Renal Pathology Atlas (Fogo, 2022). Specifically, TA/IF was graded as: Grade 0 (< 5%), Grade 1 (5-25%), Grade 2 26-50%, and Grade 3 (> 50%) of cortical area involvement. Exudative changes were defined as intracapillary leukocyte accumulation and hyaline deposits in ≥ 25% of non-sclerotic glomeruli. The primary composite outcome was ≥ 50% eGFR decline from baseline, progression to eGFR < 15 mL/min/1.73 m², dialysis initiation, or kidney transplantation. Median follow-up was 60 months (IQR 48-72). Thirty patients (9.3%) reached the composite outcome. Receiver operating characteristic analysis identified a GSGR threshold of 15.7% (AUC 0.956; sensitivity 93.3%; specificity 82.7%). Patients with GSGR ≥ 15.7% had significantly higher event rates (35.1% vs. 1.2%; p < 0.001). In multivariate analysis, high GSGR, exudative changes, and response to immunosuppressive therapy independently predicted adverse outcomes. These associations remained significant across treatment subgroups. Sensitivity analyses confirmed these associations across multiple model specifications. Anti-PLA2R positivity correlated with higher baseline proteinuria but not independently with renal outcomes. A GSGR ≥ 15.7% is a strong, independent predictor of renal progression in idiopathic MN. Incorporating GSGR and exudative changes into risk stratification may improve prognostic assessment and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.